Search
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalIt is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Categories: Glycogen Storage Disease Type IIQuinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigational[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. … Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.
Categories: Agents Acting on the Renin-Angiotensin SystemInositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawnIt is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate … These molecules have structural similarities to glucose and are involved in cellular signaling.
Mixtures: Multi II IV Vi Tab, Multipack IIHuman thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalChinese hamster ovary cell line [FDA Label]. … In particular, while human thrombin products are made from pooled human source plasma, recombinant thrombin is a human coagulation protein produced via recombinant DNA technology from a genetically modified
Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/mlHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.
Categories: Arteriolar Smooth Muscle, Agents Acting OnMethyl salicylate
go.drugbank.com/drugs/DB09543ApprovedInvestigationalVet approvedIt is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions. … The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It can be manufactured synthetically and it used as a fragrance, in foods, beverages, and liniments.
Mixtures: Re-Lieved 3 in 1 Patch, Transderm-IQCategories: Compounds used in a research, industrial, or household settingPulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug
go.drugbank.com/conditions/DBCOND0154352Drugs: PretomanidSynonyms: Pulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drugManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Synonyms: Manganese(II) gluconateMixtures: Cal-mag Plus K, Mn and Zn Caplets, Vitamin E 400 Iu With Selenium, Vitamin C & ManganeseTrihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalIn 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.